1. Home
  2. GRNQ vs BCTX Comparison

GRNQ vs BCTX Comparison

Compare GRNQ & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRNQ
  • BCTX
  • Stock Information
  • Founded
  • GRNQ 2013
  • BCTX 2014
  • Country
  • GRNQ Malaysia
  • BCTX Canada
  • Employees
  • GRNQ N/A
  • BCTX N/A
  • Industry
  • GRNQ EDP Services
  • BCTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRNQ Technology
  • BCTX Health Care
  • Exchange
  • GRNQ Nasdaq
  • BCTX Nasdaq
  • Market Cap
  • GRNQ 12.4M
  • BCTX 12.7M
  • IPO Year
  • GRNQ 2018
  • BCTX N/A
  • Fundamental
  • Price
  • GRNQ $1.50
  • BCTX $0.70
  • Analyst Decision
  • GRNQ
  • BCTX Strong Buy
  • Analyst Count
  • GRNQ 0
  • BCTX 1
  • Target Price
  • GRNQ N/A
  • BCTX $32.00
  • AVG Volume (30 Days)
  • GRNQ 33.2K
  • BCTX 776.6K
  • Earning Date
  • GRNQ 08-12-2025
  • BCTX 06-16-2025
  • Dividend Yield
  • GRNQ N/A
  • BCTX N/A
  • EPS Growth
  • GRNQ N/A
  • BCTX N/A
  • EPS
  • GRNQ N/A
  • BCTX N/A
  • Revenue
  • GRNQ $3,256,679.00
  • BCTX N/A
  • Revenue This Year
  • GRNQ N/A
  • BCTX N/A
  • Revenue Next Year
  • GRNQ N/A
  • BCTX N/A
  • P/E Ratio
  • GRNQ N/A
  • BCTX N/A
  • Revenue Growth
  • GRNQ N/A
  • BCTX N/A
  • 52 Week Low
  • GRNQ $0.80
  • BCTX $0.61
  • 52 Week High
  • GRNQ $2.50
  • BCTX $29.40
  • Technical
  • Relative Strength Index (RSI)
  • GRNQ 42.64
  • BCTX 28.70
  • Support Level
  • GRNQ $1.29
  • BCTX $0.63
  • Resistance Level
  • GRNQ $1.74
  • BCTX $0.75
  • Average True Range (ATR)
  • GRNQ 0.10
  • BCTX 0.06
  • MACD
  • GRNQ -0.02
  • BCTX 0.07
  • Stochastic Oscillator
  • GRNQ 35.69
  • BCTX 48.83

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: